Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Els, De Paepe"'
Autor:
Richard H. Osborne, Lauren M. Nelson, Sheri Fehnel, Nicole Williams, Randall H. Bender, Ryan Ziemiecki, Efi Gymnopoulou, Els De Paepe, Yannick Vandendijck, Lindsey Norcross, Esther Heijnen, Gabriela Ispas, Christy Comeaux, Benoit Callendret, Eric K. H. Chan, Jane A. Scott
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 7, Iss 1, Pp 1-10 (2023)
Abstract Background The Respiratory Infection Intensity and Impact Questionnaire (RiiQ™) is a patient-reported outcome measure designed to assess symptoms and impacts of respiratory syncytial virus (RSV) infection. This study evaluated the construc
Externí odkaz:
https://doaj.org/article/5b724d2c15ed41cd898aa8d9498f4137
Autor:
Ann R. Falsey, Kristi Williams, Efi Gymnopoulou, Stephan Bart, John Ervin, Arangassery R. Bastian, Joris Menten, Els De Paepe, Sjouke Vandenberghe, Eric K.H. Chan, Jerald Sadoff, Macaya Douoguih, Benoit Callendret, Christy A. Comeaux, Esther Heijnen
Publikováno v:
New England Journal of Medicine. 388:609-620
Autor:
Christy A Comeaux, Ann R Falsey, Kristi Williams, Stephan Bart, John E Ervin, Arangassery R Bastian, Joris Menten, Els De Paepe, Sjouke Vandenberghe, Eric K H Chan, Jerald Sadoff, Macaya Douoguih, Benoit Callendret, Esther Heijnen
Publikováno v:
Open Forum Infectious Diseases. 9
Background Respiratory syncytial virus (RSV) can cause serious lower respiratory tract disease (LRTD) among older adults. There is no licensed RSV vaccine. In CYPRESS (a randomized, double-blind, placebo-controlled, phase 2b proof-of concept trial; N
Autor:
Ann Falsey, Kristi Williams, Efi Gymnopoulou, Stephan Bart, John Ervin, Els De Paepe, Christy Comeaux, Esther Heijnen
Publikováno v:
Innovation in Aging
Respiratory syncytial virus (RSV) may cause serious lower respiratory tract disease (LRTD) in older adults, and there is currently no licensed vaccine. CYPRESS (NCT03982199) is a randomized, double-blind, placebo-controlled Phase 2b proof-of-concept
Autor:
Arangassery Rosemary Bastian, Jerald C. Sadoff, Kingsley Eze, Esther Heijnen, Bryan Murray, An Vandebosch, Christy Comeaux, Benoit Callendret, Efi Gymnopoulou, Els De Paepe, Nicolas Noulin, Rob Lambkin-Williams, Anthony Gilbert, John P. DeVincenzo, Hanneke Schuitemaker, Joris Menten, Wouter Haazen
Publikováno v:
The Journal of infectious diseases. 226(3)
Background Respiratory syncytial virus (RSV) is a significant cause of severe lower respiratory tract disease in children and older adults, but has no approved vaccine. This study assessed the potential of Ad26.RSV.preF to protect against RSV infecti
Autor:
Esther Heijnen, Hanneke Schuitemaker, Jerald C. Sadoff, Edmund Omoruyi, Wouter Haazen, Arangassery Rosemary Bastian, Christy Comeaux, Els De Paepe, Cynthia Strout, Benoit Callendret
Publikováno v:
The Journal of infectious diseases. 223(4)
Background Respiratory syncytial virus (RSV) and influenza cause significant disease burden in older adults. Overlapping RSV and influenza seasonality presents the opportunity to coadminister vaccines for both infections. This study assessed coadmini
Autor:
Arangassery Rosemary Bastian, Olivier Godeaux, Edmund Omoruyi, Hanneke Schuitemaker, Els De Paepe, Jerry Sadoff, Benoit Callendret, Robert Allen Feldman, Kristi Lynn Williams, Jenny Hendriks, Hester van Zeeburg, Johannes P. M. Langedijk
Publikováno v:
The Journal of infectious diseases. 222(6)
Background Despite the high disease burden of respiratory syncytial virus (RSV) in older adults, there is no approved vaccine. We evaluated the experimental RSV vaccine, Ad26.RSV.preF, a replication-incompetent adenovirus 26 vector encoding the F pro
Autor:
Ann R Falsey, Kristi Williams, Efi Gymnopoulou, Stephan A Bart, John E Ervin, Arangassery Rosemary Bastian, Joris Menten, Els De Paepe, Hilde de Boer, Sjoukje Vandenberghe, Eric Chan, Jerald Sadoff, Macaya Douoguih, Benoit Callendret, Christy Comeaux, Esther Heijnen
Publikováno v:
Open Forum Infectious Diseases
Background Respiratory syncytial virus (RSV) can cause serious lower respiratory tract disease (LRTD) in older adults. Despite a high burden of disease, there is currently no licensed vaccine for RSV. Here, we report the primary efficacy and immunoge
Autor:
Ann Falsey, Kristi Williams, Efi Gymnopoulou, Stephan Bart, John Ervin, Els De Paepe, Esther Heijnen, Christy Comeaux
Publikováno v:
Innovation in Aging
Respiratory syncytial virus (RSV) may cause severe lower respiratory tract disease in older adults and there is currently no approved vaccine. We assessed the safety and reactogenicity of an Ad26.RSV.preF-based vaccine in a randomized, double-blind,
Autor:
Hanneke Schuitemaker, Esther Heijnen, Bryan Murray, Nicolas Noulin, Kinglsey Eze, Benoit Callendret, Efi Gymnopoulou, Arangassery Rosemary Bastian, Christy Comeaux, Els De Paepe, Anthony Gilbert, Rob Lambkin-Williams, Jerald C. Sadoff, John P. DeVincenzo, Wouter Haazen
Publikováno v:
Open Forum Infectious Diseases
Background Despite the high disease burden of RSV in older adults and children, there is currently no approved vaccine. Ad26.RSV.preF, an experimental RSV vaccine, has demonstrated immunogenicity and tolerability in first-in-human clinical studies. T